Literature DB >> 7115635

Ritodrine in the management of fetal distress.

S Sheybany, J F Murphy, D Evans, R G Newcombe, J F Pearson.   

Abstract

The potential value of a bolus injection of ritodrine in the management of fetal distress was examined in 24 patients. Following the injection of ritodrine, uterine activity measured over a period of 14.7 +/- 6.3 (SD) min was reduced to 22 (+/- 12.4 SD)% of the pre-existing values. The cardiotocographic tracings showed a reversion to a normal or less ominous pattern in 14 of the 16 patients where this could be evaluated. The infants in the ritodrine group took less time to establish regular respirations. The perinatal neurobehaviour in the ritodrine and control groups did not differ. Two mothers who were given ritodrine and who received atropine premedication developed tachycardia and marked systolic hypertension. The administration of a bolus of ritodrine may have a place in the management of fetal distress when caesarean section is unavoidably delayed, but atropine premedication must be avoided as the combination can lead to potentially serious cardiovascular complications.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7115635     DOI: 10.1111/j.1471-0528.1982.tb05098.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  3 in total

1.  A glycopyrrolate-ritodrine drug-drug interaction.

Authors:  J I Simpson; J P Giffin
Journal:  Can J Anaesth       Date:  1988-03       Impact factor: 5.063

Review 2.  Acute tocolysis for uterine tachysystole or suspected fetal distress.

Authors:  Sebastian J Leathersich; Joshua P Vogel; Thach Son Tran; G Justus Hofmeyr
Journal:  Cochrane Database Syst Rev       Date:  2018-07-04

3.  Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.

Authors:  Tsuyoshi Murata; Hyo Kyozuka; Shun Yasuda; Toma Fukuda; Teruyoshi Tanaka; Keiya Fujimori
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.